Skip to content

Advertisement

  • SELECTED PRESENTATION
  • Open Access

Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties

  • ,
  • ,
  • and
The Journal of Headache and PainOfficial Journal of the Italian Society for the Study of Headaches4:00019

https://doi.org/10.1007/s101940300019

Abstract

Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.

  • Key words Triptans
  • Indications

Notes

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement